A randomized, Double-blind, Placebo and Active controlled, Multicenter, Phase 3 Study to Access the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination with Methotrexate (MTX) to Subjects with Moderately to Severely Active Rheumatoid Arthritis who Are Naive to MTX Therapy | India Science, Technology & Innovation - ISTI Portal

×

Acces sibility Controls

A randomized, Double-blind, Placebo and Active controlled, Multicenter, Phase 3 Study to Access the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination with Methotrexate (MTX) to Subjects with Moderately to Severely Active Rheumatoid Arthritis who Are Naive to MTX Therapy

Implementing Organization

All India Institute of Medical Sciences

Principal Investigator

Dr Uma Kumar

Professor & Head

|

All India Institute of Medical Sciences

Related Research

Quick Information

Area of Research

Life Sciences & Biotechnology

Focus Area

Orthopedics

Start Year

2018

End Year

2022

Sanction Amount

₹ 10.00 L

Status

Completed

Output

No. of Research Paper

00

Technologies (If Any)

00

No. of PhD Produced

N/A

Startup (If Any)

00

No. of Patents

Filed :00

Grant :00